KN

Knowles Corporation (KN) - 2024 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2024. Knowles Corporation is a leading manufacturer of specialty electronic components serving medtech, defense, and industrial markets. The company operates through two reportable segments: Precision Devices (PD) (capacitors and RF filters) and MedTech & Specialty Audio (MSA) (microphones and speakers). A major strategic shift occurred in 2024 with the divestiture of the Consumer MEMS Microphones (CMM) business to Syntiant Corp., which is now reported as discontinued operations.

Key Financial Metrics (2024)

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased 21.2% to $553.5 million, driven primarily by the November 2023 acquisition of Cornell Dubilier (CD) in the PD segment and higher shipping volumes in the MSA segment.
• Profitability Decline (GAAP): Net earnings from continuing operations dropped 67% to $23.4 million. This was primarily due to a shift from a $28.3 million tax benefit in 2023 to an $11.3 million tax provision in 2024, alongside higher interest expense ($16.3 million vs. $5.4 million) and operating expenses related to the CD acquisition.
• Discontinued Operations Impact: The company reported a net loss of $261.2 million from discontinued operations, largely due to a $262.5 million goodwill impairment charge related to the divested CMM business, partially offset by a gain on the sale of the business.
• Segment Performance:
  • Precision Devices: Revenues rose 35.5% to $300.0 million. However, GAAP EBIT margin compressed to 4.9% (from 11.3%) due to acquisition-related amortization and restructuring costs.
  • MedTech & Specialty Audio: Revenues grew 7.7% to $253.5 million. EBIT margin improved to 38.5% (from 36.7%) driven by favorable product mix and cost reductions.

Guidance, Outlook, and Risks

• Strategic Transformation: Management views the CMM divestiture as a strategic shift to focus on higher-value industrial technology markets (defense, medtech, electrification). The company expects to incur dis-synergies and is optimizing cost structures.
• Capital Allocation: The company remains committed to share repurchases. In February 2025, the Board increased the repurchase authorization by an additional $150 million. As of year-end, $44.0 million remained under the prior authorization.
• Capital Expenditures: Expected to range between 3% and 5% of revenues in 2025.
• Key Risks:
  • Customer Concentration: WS Audiology A/S accounted for 14% of total revenues in 2024. The MSA segment relies heavily on a limited number of customers (top 5 accounted for ~81% of MSA revenue).
  • Supply Chain: Reliance on specialized suppliers and foundries, with significant manufacturing exposure in Asia (China, Philippines, Malaysia).
  • Debt Covenants: The company must maintain specific leverage and interest coverage ratios under its credit agreement. Management expects to remain in compliance.
  • Commodity Prices: Exposure to fluctuations in precious metals (palladium, gold) and foreign currency exchange rates.

Investor Verification Checklist

• Discontinued Operations: Verify the treatment of the $262.5 million goodwill impairment and the $1.7 million gain on sale of the CMM business to understand the full impact on the bottom line.
• Tax Rate Volatility: Review the reconciliation of the effective tax rate, noting the $15.1 million valuation allowance release in 2023 versus the $18.2 million accrual in 2024 (primarily in discontinued ops).
• Acquisition Integration: Assess the impact of the Cornell Dubilier acquisition on intangible asset amortization ($17.0 million in 2024) and its effect on future margins.
• Customer Dependency: Monitor the health of WS Audiology A/S and other top MSA customers, given the high concentration risk.
• Debt Structure: Confirm the repayment schedule for the $72.7 million Seller Note due in November 2025 and the status of the $400 million revolving credit facility.